Patent Expiration of J&J’s Blockbuster Drug Stelara & Other Headwinds J&J lost ... the sector and S&P 500 Index as seen in the chart below. It is also trading above its 200-day and 50-day ...
Zacks Investment Research on MSN4d
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanJ&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ... is a prescription drug discount card program ...
Navitus will remove Stelara from formulary on July 1, 2025. Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Four biosimilars for Stelara have launched in the United States ... The FDA has approved seven biosimilars for the drug, though patent litigation has blocked their launches until now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback